Antiarrhythmic therapy in atrial fibrillation

Cites (263)

Items 201–261 of 261

1. Calcium-Activated Nonselective Cation Channels in Mammalian Cardiomyocytes
   Romain Guinamard, Marie Demion, Aurélien Chatelier, Patrick Bois · 2006 · Trends in Cardiovascular Medicine
2. Inhibitory effects of JTV‐519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea‐pig hearts
   Haruaki Nakaya, Yoshie Furusawa, Takehiko Ogura, Masaji Tamagawa, Hiroko Uemura · 2000 · British Journal of Pharmacology
3. Clinical Experience with Dofetilide in the Treatment of Patients with Atrial Fibrillation
   Eric N. Prystowsky, Scott Freeland, Nancy A. Branyas, David P. Rardon, Richard Ira Fogel, Benzy J. Padanilam, JANET S. RIPPY · 2003 · Journal of Cardiovascular Electrophysiology
4. Angiotensin II modulates cardiac Na+ channels in neonatal rat.
   J. Randall Moorman, Glenn E. Kirsch, Antonio E. Lacerda, Arthur M Brown · 1989 · Circulation Research
5. The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model
   Eric I. Rossman, Kun Liu, Gwen A. Morgan, Robert E. Swillo, Julie A. Krueger, Stephen J. Gardell, John A. Butera, Matthew Gruver, Joel Kantrowitz, Hal S. Feldman et al. · 2009 · Journal of Pharmacology and Experimental Therapeutics
6. Effects of Chronic Gap Junction Conduction–Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs
   Gabriel Laurent, Howard M. Leong-Poi, Iqwal Mangat, Gordon Willy Pak Ling Moe, Xudong Hu, Petsy Pui‐Sze So, Emidio Tarulli, Andrew Ramadeen, Eric I. Rossman, James K. Hennan et al. · 2009 · Circulation Arrhythmia and Electrophysiology
7. In Vitro and In Vivo Effects of the Atrial Selective Antiarrhythmic Compound AVE1231
   KLAUS J. WIRTH, Joachim Brendel, Klaus Steinmeyer, Dominik Linz, Hartmut Rütten, Heinz Gögelein · 2007 · Journal of Cardiovascular Pharmacology
8. A Benefit-Risk Assessment of Class III Antiarrhythmic Agents
   Bente Brendorp, Ole Dyg Pedersen, Christian Tobias Torp-Pedersen, Najia Sahebzadah, Lars Køber · 2002 · Drug Safety
9. Ionic Mechanism of Ibutilide in Human Atrium: Evidence for a Drug-Induced Na+ Current Through a Nifedipine Inhibited Inward Channel
   Kai S. Lee, Esther W. Lee · 1998 · Journal of Pharmacology and Experimental Therapeutics
10. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium
    John C. Shryock, Luiz Belardinelli · 2007 · British Journal of Pharmacology
11. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure
    Tonje Amb Aksnes, Arnljot Flaa, Arne H. Strand, Sverre Erik Kjeldsen · 2006 · Journal of Hypertension
12. Differential Atrial versus Ventricular Activities of Class III Potassium Channel Blockers
    Elizabeth P. Baskin, JR Lynch · 1998 · Journal of Pharmacology and Experimental Therapeutics
13. Sodium Calcium Exchange as a Target for Antiarrhythmic Therapy
    Karin R. Sipido, András Varró, David A. Eisner · 2006 · Springer eBooks
14. Local effects and mechanisms of antiarrhythmic peptide AAP10 in acute regional myocardial ischemia: electrophysiological and molecular findings
    Joanna Jozwiak, Stefan Dhein · 2008 · Naunyn-Schmiedeberg s Archives of Pharmacology
15. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes
    Erich Wettwer, Herbert M. Himmel, Gregory J. Amos, Qi Li, Franz Metzger, Ursula Ravens · 1998 · British Journal of Pharmacology
16. Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog
    Leif G. Carlsson, Denis Chartier, Stanley Nattel · 2006 · Journal of Cardiovascular Pharmacology
17. Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target
    Dobromir Dobrev · 2009 · Naunyn-Schmiedeberg s Archives of Pharmacology
18. The plateau outward current in canine ventricle, sensitive to 4‐aminopyridine, is a constitutive contributor to ventricular repolarization
    Arun Sridhar, Daise Nunes Queiroz da Cunha, Véronique A. Lacombe, Qinlian Zhou, Jeffrey J. Fox, Robert L. Hamlin, Cynthia A. Carnes · 2007 · British Journal of Pharmacology
19. Atrial Fibrillation in Rats Induced by Rapid Transesophageal Atrial Pacing during Brief Episodes of Asphyxia: A New In Vivo Model
    Ketil Haugan, Henrik Rye Lam, Carsten Knudsen, Jørgen S. Petersen · 2004 · Journal of Cardiovascular Pharmacology
20. Blockade by NIP-142, an Antiarrhythmic Agent, of Carbachol-Induced Atrial Action Potential Shortening and GIRK1/4 Channel
    Tomoyuki Matsuda, Mie Ito, Sayoko Ishimaru, Noriko Tsuruoka, Tomoaki Saito, Naoko Iida‐Tanaka, Norio Hashimoto, Toru Yamashita, Nobutomo Tsuruzoe, Hikaru Tanaka et al. · 2006 · Journal of Pharmacological Sciences
21. Discovery of (2S,4R)-1-(2-Aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic Acid Hydrochloride (GAP-134)13, an Orally Active Small Molecule Gap-Junction Modifier for the Treatment of Atrial Fibrillation
    John A. Butera, Bjarne Due Larsen, James K. Hennan, Edward H. Kerns, Li Di, Asaf Alimardanov, Robert E. Swillo, Gwen A. Morgan, Kun Liu, Qiang Wang et al. · 2009 · Journal of Medicinal Chemistry
22. In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate
    Christopher P. Regan, Audrey A. Wallace, Hillary K. Cresswell, Charity L. Atkins, Joseph J. Lynch · 2006 · Journal of Pharmacology and Experimental Therapeutics
23. Direct Pro-Arrhythmogenic Effects of Angiotensin II can be Suppressed by AT1 Receptor Blockade in Human Atrial Myocardium
    Dirk von Lewinski, Jens Kockskämper, Sven‐Ulrich Rübertus, Danan Zhu, Jan Dieter Schmitto, Friedrich A. Schöndube, Gerd P Hasenfuss, Burkert Mathias Pieske · 2008 · European Journal of Heart Failure
24. Nonchannel drug targets in atrial fibrillation
    Andreas Goette, Uwe Lendeckel · 2004 · Pharmacology & Therapeutics
25. Effects of JTV-519, a novel anti-ischaemic drug, on the delayed rectifier K + current in guinea-pig ventricular myocytes
    Kuninori Kiriyama, Tatsuto Kiyosue, J.-C. Wang, Kazuhiro Dohi, Makoto Arita · 2000 · Naunyn-Schmiedeberg s Archives of Pharmacology
26. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study
    Craig M. Pratt, James A. Reiffel, Kenneth A. Ellenbogen, Gerald V. Naccarelli, Peter Russell Kowey · 2009 · American Heart Journal
27. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes
    Alexander Bachmann, Ilona Gutcher, Karin Kopp, Joachim Brendel, RALPH F. BOSCH, Andreas E Busch, Heinz Gögelein · 2001 · Naunyn-Schmiedeberg s Archives of Pharmacology
28. Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles.
    Andreas Ohler, Ursula Ravens · 1994 · Journal of Pharmacology and Experimental Therapeutics
29. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
    Karsten Knobloch, Joachim Brendel, Björn Rosenstein, Markus Bleich, Andreas E Busch, KLAUS J. WIRTH · 2004 · PubMed
30. Acetylcholine-Induced K+ Current in Amphibian Atrial Cells
    Yasunori Momose, Wayne R. Giles, G. Szabo · 1984 · Biophysical Journal
31. Efficacy of Azimilide for the Maintenance of Sinus Rhythm in Patients With Paroxysmal Atrial Fibrillation in the Presence and Absence of Structural Heart Disease
    Charles R. Kerr, Stuart J. Connolly, Peter Russell Kowey, Richard L. Page, Edward L.C. Pritchett, Mikhail Ya. Ruda, Witold Rużyłło, William E. Wilkinson · 2006 · The American Journal of Cardiology
32. Electrophysiologic actions of dl-sotalolin patients with persistent atrial fibrillation
    Hung‐Fat Tse, Chu‐Pak Lau · 2002 · Journal of the American College of Cardiology
33. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling)
    ANDREAS GOETTE, Alicja Bukowska, Uwe Lendeckel · 2007 · Current Opinion in Pharmacology
34. Two distinct types of inwardly rectifying K+ channels in bull‐frog atrial myocytes.
    R B Clark, Toshiaki Nakajima, Wayne R. Giles, K Kanai, Yasunori Momose, Gabor Tamas Szabo · 1990 · The Journal of Physiology
35. A Multiple Ion Channel Blocker, NIP‐142, for the Treatment of Atrial Fibrillation
    Hikaru Tanaka, Norio Hashimoto · 2007 · Cardiovascular Drug Reviews
36. Effect of Atrial Electrical Remodeling on the Efficacy of Antiarrhythmic Drugs: Comparison of Amiodarone with IKr‐ and Ito/IKur‐Blockade In Vivo
    Dominik Linz, Freni Afkham, Gabi Itter, Hartmut Rütten, KLAUS J. WIRTH · 2007 · Journal of Cardiovascular Electrophysiology
37. Blocking Characteristics of hKv1.5 and hKv4.3/hKChIP2.2 After Administration of the Novel Antiarrhythmic Compound AZD7009
    Frida Persson, Leif G. Carlsson, Göran Duker, Ingemar Jacobson PhD · 2005 · Journal of Cardiovascular Pharmacology
38. Inhibitory effects of polyunsaturated fatty acids on Kv4/KChIP potassium channels
    Linda M. Boland, Michelle M. Drzewiecki, Gabriela Timoney, Erin Casey · 2009 · American Journal of Physiology-Cell Physiology
39. Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation?
    Irina Savelieva, A. John Camm · 2007 · American Heart Journal
40. Pharmacological Approaches in the Treatment of Atrial Fibrillation
    Juan Luis Tamargo, Ricardo Caballero, Eva Delpón · 2004 · Current Medicinal Chemistry
41. Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009
    J. Christoph Geller, Kenneth Egstrup, Piotr Kułakowski, Mårten Rosenqvist, Maria Aunes-Jansson, Anders Berggren, Nils G. Edvardsson, Philip T. Sager, Harry J.G.M. Crijns · 2009 · The Journal of Clinical Pharmacology
42. Genetics of Atrial Fibrillation
    Steven A. Lubitz, B. Alexander Yi, Patrick T. Ellinor · 2008 · Cardiology Clinics
43. The anti-arrhythmic peptide AAP10 remodels Cx43 and Cx40 expression and function
    Jennifer A. Easton, Jørgen S. Petersen, Patricia E. Martin · 2009 · Naunyn-Schmiedeberg s Archives of Pharmacology
44. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro
    Lena Löfberg, Ingemar Jacobson, Leif G. Carlsson · 2006 · EP Europace
45. Drug development for treatment of cardiac arrhythmias: targeting the gap junctions
    Andrew L. Wit, Heather S. Duffy · 2007 · American Journal of Physiology-Heart and Circulatory Physiology
46. Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate
    Nikolaos Fragakis, A. Bikias, Ioannis Delithanasis, Melanie Konstantinidou, N. Liakopoulos, M. Kozirakis, George Katsaris · 2008 · EP Europace
47. Enalapril Preserves Sinus Node Function in a Canine Atrial Fibrillation Model Induced by Rapid Atrial Pacing
    Masao Sakabe, Akira Fujiki, Kunihiro Nishida, Masataka Sugao, Hidehiko Nagasawa, Takayuki Tsuneda, Koichi Mizumaki, Hiroshi Inoue · 2005 · Journal of Cardiovascular Electrophysiology
48. Pharmacological Treatment of Atrial Fibrillation: Mechanisms of Action and Efficacy of Class III Drugs
    Federico Lombardi, P Terranova · 2006 · Current Medicinal Chemistry
49. Directionality in Drug Action on Sodium–Calcium Exchange
    Denis Noble, M. P. Blaustein · 2007 · Annals of the New York Academy of Sciences
50. Vernakalant hydrochloride for the treatment of atrial fibrillation
    Dariusz Kozłowski, Szymon Budrejko, Gregory Y.H. Lip, Dimitri P. Mikhailidis, Jacek Rysz, Grzegorz Raczak, Maciej Banach · 2009 · Expert Opinion on Investigational Drugs
51. Transient receptor potential: a large family of new channels of which several are involved in cardiac arrhythmiaThis article is one of a selection of papers from the NATO Advanced Research Workshop on Translational Knowledge for Heart Health (published in part 1 of a 2-part Special Issue).
    Guy Vassort, Julio L. Álvarez · 2009 · Canadian Journal of Physiology and Pharmacology
52. Frequency-dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol
    Miklós Németh, András Varró, László Virág, Ottó Hála, D. Thormählen, Julius Gyula Papp · 1997 · Journal of Cardiovascular Pharmacology and Therapeutics
53. Tedisamil in a Chronic Canine Model of Atrial Flutter
    Peter Fischbach, Peter V. Johnston, Gregory S. Friedrichs, Benedict Robert Lucchesi · 1999 · Journal of Cardiovascular Pharmacology
54. Is There a Role for Statins in Atrial Fibrillation?
    David E. Dawe, Vignendra Ariyarajah, Aliasghar Khadem · 2009 · Pacing and Clinical Electrophysiology
55. Lipid-Altering Therapy and Atrial Fibrillation
    Justin Matthew Bachmann, Maulik D. Majmudar, CHRISTINE M. TOMPKINS, Roger Scott Blumenthal, Joseph Edward Marine · 2008 · Cardiology in Review
56. Effects of Azimilide on the Muscarinic Acetylcholine Receptor-Operated K+ Current and Experimental Atrial Fibrillation in Guinea-Pig Hearts
    Atsushi Nishida, Yoshie Reien, Takehiko Ogura, Hiroko Uemura, Masaji Tamagawa, Hideo Yabana, Haruaki Nakaya · 2007 · Journal of Pharmacological Sciences
57. Do we need pharmacological therapy for atrial fibrillation in the ablation era?
    Samuel Lévy · 2006 · Journal of Interventional Cardiac Electrophysiology
58. The relationship between gap junctional remodeling and human atrial fibrillation.
    Li Daqiang, Yi-bai Feng, Huiqin Zhang · 2004 · PubMed
59. Tedisamil in Coronary Disease: Additional Benefits in the Therapy of Atrial Fibrillation?
    Lionel Henry Opie · 2003 · Journal of Cardiovascular Pharmacology and Therapeutics
60. Evaluating the impact of atrial dilatation on atrial calcium cycling
    David R. Van Wagoner · 2008 · European Heart Journal
61. Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators
    DAVID S. SCHWARTZMAN, Mark N. Harvey, ROBERT H. HOYT, Jodi L. Koehler, Michael R. Ujhelyi, David E. Euler · 2006 · EP Europace